Cargando…
The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold
Ebolaviruses cause hemorrhagic fever with up to 90% lethality and in fatal cases, are characterized by early suppression of the host innate immune system. One of the proteins likely responsible for this effect is VP24. VP24 is known to antagonize interferon signaling by binding host karyopherin α pr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285596/ https://www.ncbi.nlm.nih.gov/pubmed/22383882 http://dx.doi.org/10.1371/journal.ppat.1002550 |
_version_ | 1782224489501687808 |
---|---|
author | Zhang, Adrianna P. P. Bornholdt, Zachary A. Liu, Tong Abelson, Dafna M. Lee, David E. Li, Sheng Woods, Virgil L. Saphire, Erica Ollmann |
author_facet | Zhang, Adrianna P. P. Bornholdt, Zachary A. Liu, Tong Abelson, Dafna M. Lee, David E. Li, Sheng Woods, Virgil L. Saphire, Erica Ollmann |
author_sort | Zhang, Adrianna P. P. |
collection | PubMed |
description | Ebolaviruses cause hemorrhagic fever with up to 90% lethality and in fatal cases, are characterized by early suppression of the host innate immune system. One of the proteins likely responsible for this effect is VP24. VP24 is known to antagonize interferon signaling by binding host karyopherin α proteins, thereby preventing them from transporting the tyrosine-phosphorylated transcription factor STAT1 to the nucleus. Here, we report that VP24 binds STAT1 directly, suggesting that VP24 can suppress at least two distinct branches of the interferon pathway. Here, we also report the first crystal structures of VP24, derived from different species of ebolavirus that are pathogenic (Sudan) and nonpathogenic to humans (Reston). These structures reveal that VP24 has a novel, pyramidal fold. A site on a particular face of the pyramid exhibits reduced solvent exchange when in complex with STAT1. This site is above two highly conserved pockets in VP24 that contain key residues previously implicated in virulence. These crystal structures and accompanying biochemical analysis map differences between pathogenic and nonpathogenic viruses, offer templates for drug design, and provide the three-dimensional framework necessary for biological dissection of the many functions of VP24 in the virus life cycle. |
format | Online Article Text |
id | pubmed-3285596 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-32855962012-03-01 The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold Zhang, Adrianna P. P. Bornholdt, Zachary A. Liu, Tong Abelson, Dafna M. Lee, David E. Li, Sheng Woods, Virgil L. Saphire, Erica Ollmann PLoS Pathog Research Article Ebolaviruses cause hemorrhagic fever with up to 90% lethality and in fatal cases, are characterized by early suppression of the host innate immune system. One of the proteins likely responsible for this effect is VP24. VP24 is known to antagonize interferon signaling by binding host karyopherin α proteins, thereby preventing them from transporting the tyrosine-phosphorylated transcription factor STAT1 to the nucleus. Here, we report that VP24 binds STAT1 directly, suggesting that VP24 can suppress at least two distinct branches of the interferon pathway. Here, we also report the first crystal structures of VP24, derived from different species of ebolavirus that are pathogenic (Sudan) and nonpathogenic to humans (Reston). These structures reveal that VP24 has a novel, pyramidal fold. A site on a particular face of the pyramid exhibits reduced solvent exchange when in complex with STAT1. This site is above two highly conserved pockets in VP24 that contain key residues previously implicated in virulence. These crystal structures and accompanying biochemical analysis map differences between pathogenic and nonpathogenic viruses, offer templates for drug design, and provide the three-dimensional framework necessary for biological dissection of the many functions of VP24 in the virus life cycle. Public Library of Science 2012-02-23 /pmc/articles/PMC3285596/ /pubmed/22383882 http://dx.doi.org/10.1371/journal.ppat.1002550 Text en Zhang et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Zhang, Adrianna P. P. Bornholdt, Zachary A. Liu, Tong Abelson, Dafna M. Lee, David E. Li, Sheng Woods, Virgil L. Saphire, Erica Ollmann The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold |
title | The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold |
title_full | The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold |
title_fullStr | The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold |
title_full_unstemmed | The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold |
title_short | The Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal Fold |
title_sort | ebola virus interferon antagonist vp24 directly binds stat1 and has a novel, pyramidal fold |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285596/ https://www.ncbi.nlm.nih.gov/pubmed/22383882 http://dx.doi.org/10.1371/journal.ppat.1002550 |
work_keys_str_mv | AT zhangadriannapp theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT bornholdtzacharya theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT liutong theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT abelsondafnam theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT leedavide theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT lisheng theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT woodsvirgill theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT saphireericaollmann theebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT zhangadriannapp ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT bornholdtzacharya ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT liutong ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT abelsondafnam ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT leedavide ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT lisheng ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT woodsvirgill ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold AT saphireericaollmann ebolavirusinterferonantagonistvp24directlybindsstat1andhasanovelpyramidalfold |